Induction chemotherapy in head and neck cancer: closer to an answer?

摘要

The TAX 324 trial was an important study that re-emphasised induction chemotherapy as a potential management option in locally advanced head and neck cancer.1 Noteworthy isthatthe overall and progression-free survival advantages of docetaxel, cisplatin, and fluorouracil (TPF) compared with cisplatin and fluorouracil (PF) are sustained with further follow-up.2 TPF is now accepted as a better induction regimen than PF; however, the role of induction chemotherapy in the overall treatment of locally advanced head and neck cancer is still unclear.